title: Cold reactive lymphocytotoxic antibodies in pulmonary tuberculosis: correlation with disease activity and HLA.
abstract: Cold reactive lymphocytotoxic antibodies (LCA) are more reactive in cold than at 37 degrees C and occur following infection, immunization or vaccination and in various autoimmune diseases. In the present study, LCA activity against T and B-lymphocytes has been investigated in patients with pulmonary tuberculosis (PTB), their various clinical sub-groups and consanguineous relatives. Further, the relevance of HLA factors in LCA activity was analyzed. The sera from 144 PTB patients, 52 family contacts and 52 healthy individuals were tested for presence of LCAs by a modified two-stage NIH microlymphocytotoxicity assay. A significant increase in LCA activity against both T (32.6% vs 5.7%, P < 0.0001) and B (59.7% vs 13.4%, P < 0.0000001) cells was observed in PTB patients as compared to healthy controls. There was no correlation between serum LCA activity and sputum acid-fast bacilli status. However, only B cell LCAs revealed significant increase in parallel to disease advancement as assessed by X-ray chest examination. Further, LCA activity was more pronounced in drug responders than drug failure group of patients. No significant difference in the distribution of HLA class I and class II antigens was observed between LCA positive and LCA negative patients. However, panel cells carrying HLA-A1, -A11 and -DR3 were often found reactive in LCA positive patient sera. In household family contacts, LCAs were significantly increased only against B cells as compared to healthy controls (38.4% vs 13.4%, P < 0.01). This study suggests that Mycobacterium tuberculosis infection/exposure could account for the occurrence of LCAs in pulmonary tuberculosis and the strength of these antibodies is related to disease severity and the extent of lung involvement.
authors.affiliation: Department of Histocompatibility and Immunogenetics, All India Institute of Medical Sciences, New Delhi 110 029, India. lingam@cmgm.stanford.edu
authors.forename: R
authors.initials: R
authors.lastname: Rajalingam
authors.forename: N K
authors.initials: NK
authors.lastname: Mehra
authors.forename: R C
authors.initials: RC
authors.lastname: Jain
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000097:blood*; D001402:B-Lymphocytes / Q000276:immunology; D016022:Case-Control Studies; D005190:Family; D005260:Female; D006680:HLA Antigens; D006801:Humans; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*
chemical_list: D000961:Antilymphocyte Serum; D006680:HLA Antigens